Haemophagocytic lymphohistiocytosis (HLH) is an extremely rare haematological disorder. It occurs when there is an uncontrollable proliferation of hyper-activated macrophages and T-lymphocytes. The hyper-activated macrophages engulf haematopoietic cells resulting in a deregulated immune system, which in turn attacks various tissues in the body. The weakened body becomes susceptible to infection.
This report provides the current incident population for Haemophagocytic lymphohistiocytosis across 14 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Denmark, Norway, Sweden, Finland, Netherlands, Brazil and Japan) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from our analysis team, several of the main symptoms and co-morbidities of HLH have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for HLH include:
• Autoimmune conditions
• Leukaemia
• Lymphomas
• HSCT
• Infection (especially with EBV)
• Diabetes
• Obesity
• COPD
• Heart Failure
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global Haemophagocytic lymphohistiocytosis market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the incidence of the subdivided types of Haemophagocytic lymphohistiocytosis and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Haemophagocytic lymphohistiocytosis’s incident population.
• Identify sub-populations within Haemophagocytic lymphohistiocytosis which require treatment.
• Gain an understanding of the specific markets that have the largest number of Haemophagocytic lymphohistiocytosis disease patients.
'
Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key comorbid conditions/Features associated with the disease
• Methodology for quantification of patient numbers
• Top-line prevalence for HLH
• Features of HLH patients
o Classification of HLH
o Aetiology of Secondary HLH
• Symptoms of HLH
o Symptoms of Primary HLH
o Symptoms of Secondary HLH
• Abbreviations used in the report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
List of Tables
• Incidence of HLH, total (000s)
• Incidence of HLH, males (000s)
• Incidence of HLH, females (000s)
• HLH patients by type, total (000s)
• Secondary HLH patients by aetiology, total (000s)
• Primary HLH patients with Hepatosplenomegaly, total (000s)
• Primary HLH patients with Cytopenia, total (000s)
• Primary HLH patients with Hypertriglyceridemia, total (000s)
• Primary HLH patients with Hypofibrinogenemia, total (000s)
• Primary HLH patients with Elevated Fibrin, total (000s)
• Primary HLH patients with Decreased NK-Cell Activity, total (000s)
• Secondary HLH patients with Hepatosplenomegaly, total (000s)
• Secondary HLH patients with Cytopenia, total (000s)
• Secondary HLH patients with Hypertriglyceridemia, total (000s)
• Secondary HLH patients with Hypofibrinogenemia, total (000s)
• Secondary HLH patients with Elevated Fibrin, total (000s)
• Secondary HLH patients with Decreased NK-Cell Activity, total (000s)
• Abbreviations and Acronyms used in the report
• USA Incidence of HLH by 5-yr age cohort, males (000s)
• USA Incidence of HLH by 5-yr age cohort, females (000s)
• Canada Incidence of HLH by 5-yr age cohort, males (000s)
• Canada Incidence of HLH by 5-yr age cohort, females (000s)
• France Incidence of HLH by 5-yr age cohort, males (000s)
• France Incidence of HLH by 5-yr age cohort, females (000s)
• Germany Incidence of HLH by 5-yr age cohort, males (000s)
• Germany Incidence of HLH by 5-yr age cohort, females (000s)
• Italy Incidence of HLH by 5-yr age cohort, males (000s)
• Italy Incidence of HLH by 5-yr age cohort, females (000s)
• Spain Incidence of HLH by 5-yr age cohort, males (000s)
• Spain Incidence of HLH by 5-yr age cohort, females (000s)
• UK Incidence of HLH by 5-yr age cohort, males (000s)
• UK Incidence of HLH by 5-yr age cohort, females (000s)
• Denmark Incidence of HLH by 5-yr age cohort, males (000s)
• Denmark Incidence of HLH by 5-yr age cohort, females (000s)
• Norway Incidence of HLH by 5-yr age cohort, males (000s)
• Norway Incidence of HLH by 5-yr age cohort, females (000s)
• Sweden Incidence of HLH by 5-yr age cohort, males (000s)
• Sweden Incidence of HLH by 5-yr age cohort, females (000s)
• Finland Incidence of HLH by 5-yr age cohort, males (000s)
• Finland Incidence of HLH by 5-yr age cohort, females (000s)
• Netherlands Incidence of HLH by 5-yr age cohort, males (000s)
• Netherlands Incidence of HLH by 5-yr age cohort, females (000s)
• Brazil Incidence of HLH by 5-yr age cohort, males (000s)
• Brazil Incidence of HLH by 5-yr age cohort, females (000s)
• Japan Incidence of HLH by 5-yr age cohort, males (000s)
• Japan Incidence of HLH by 5-yr age cohort, females (000s)
